Loading...
Loading...
- At Pipeline Day, Pfizer Inc PFE forecasts annual revenue from its mRNA vaccine portfolio could reach $10-$15 billion by 2030.
- Last month in its Q3 earnings release, Pfizer raised its forecast for 2022 sales of its COVID-19 vaccine by $2 billion to $34 billion.
- After the successful COVID-19 vaccine, Pfizer and BioNTech SE BNTX initiated a Phase 1 study to evaluate the safety, tolerability, and immunogenicity of a next-generation COVID-19 vaccine candidate also based on mRNA technology.
- Related: After Famed COVID-19 Pill, Pfizer Inks Research Pact For Another Antiviral Candidate.
- Pfizer also expects to lose $17 billion in annual sales between 2025-2030 due to the patent expirations, Chief Commercial Officer Angela Hwang said in an investor presentation.
- Some flagship products to lose exclusivity by 2030 include Eliquis, Ibrance, Xeljanz, and Xtandi.
- Pfizer's revenue is expected to top $100 billion this year - more than double its pre-pandemic level, Reuters reported on solid growth from its COVID-19 vaccine and treatment Paxlovid.
- Analysts expect COVID-19 vaccine revenues to drop sharply beginning in 2023 and see sales of Pfizer's Comirnaty at around $6.7 billion in 2027.
- Price Action: PFE shares are up 2.13% at $53.27 during the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in